Category: Merck

Pfizer And Merck Go For An Even Longer Throw Of The Javelin

Pfizer and Merck KGaA’s tweaks to the Javelin Lung 100 study of their PD-L1 antibody avelumab, which will delay its readout by almost two years, look like a painful but necessary adjustment to commercial realities in this competitive cancer indication. The changes will more than double the size of the study, in first-line non-small cell lung cancer, and push data out to mid-2019.

FDA OKs Merck’s allergen extract to treat house dust mite-induced allergic rhinitis

The FDA approves Merck’s Odactra, the first allergen extract that is administered sublingually to treat house dust mite-induced nasal inflammation , with or without eye inflammation in people between the ages of 18 and 65. Odactra, a once-daily tablet that rapidly dissolves under the tongue, exposes patients to house dust mite allergens with the aim of gradually training the immune system to reduce the frequency and severity of nasal and eye allergy symptoms. It is taken year-round.

Merck profit soars on new drugs, expects better 2017

Merck CEO Kenneth Frazier on Thursday said he’s encouraged by an initial meeting he and other pharmaceutical executives had Tuesday with Trump, who has said drugmakers have been The pharmaceutical industry has come under fire in recent months over soaring drug prices, which have been blasted by patients, doctors, politicians and others. Drug companies and investors have been alternatively worried that the Trump administration and Congress will move to reduce prices, and cheered by hopes that they will help them increase profits by reducing taxes and reducing regulations so they can bring new drugs to market faster.

Merck 2017 forecast eases concerns over royalty payments, dollar

Merck & Co Inc reported better-than-expected U.S. quarterly sales for its key cancer drug, Keytruda, and forecast largely in-line 2017 results, which some analysts said allayed concerns over the impact of a strong dollar and royalty payments. The logo of Merck is pictured in this illustration photograph in Cardiff, California April 26, 2016.

MSD for Mothers Commits $10 Million and Business Expertise to the…

MSD for Mothers Commits $10 Million and Business Expertise to the Global Financing Facility to Help End Preventable Deaths of Mothers MSD, known as Merck & Co., Inc., Kenilworth, N.J., U.S.A., inside the United States and Canada, announced today its $10 million commitment to the Global Financing Facility in support of Every Woman Every Child to improve maternal and child health in low- and lower-middle-income countries worldwide through its MSD for Mothers initiative.

For Merck, Keytruda Is ‘Extraordinarily Positive’ : More Squawk From Jim Cramer

Merck’s lung cancer treatment will get a speedy review by the FDA, but it ‘knows better than to go out and give false hope,’ TheStreet’s Jim Cramer said. Shares of Merck were higher in late morning trading Wednesday, after the company announced the U.S. Food and Drug Administration would make a decision by May 10 on its lung cancer treatment that combines the immune system-boosting drug Keytruda with chemotherapy.

Therapy Focus – Immunotherapy Closes In On Triple-Negative Tumors

Celgene admitted as much last week by saying it would not push a promising Abraxane-containing chemotherapy regimen into pivotal trials in this Several studies are already under way, most notably a large first-line phase III trial of Abraxane plus Roche’s anti-PD-L1 antibody Tecentriq. Early data are encouraging, and hopes are high that meaningful survival benefits will emerge in the next couple of years.

DPP IV Inhibitors

… Global Diabetes Expenditure: Opportunity Indicator for DPP-IV Inhibitor Market………….. II-5 Table 3: Global Health Expenditure on Diabetes by Region (2015): Spending (in US$ Billion) by People Diagnosed with Diabetes in the Age Group 20-79 …